×
MiMedx Net Current Debt 2010-2025 | MDXG
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
MiMedx net current debt from 2010 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
MiMedx Net Current Debt 2010-2025 | MDXG
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
MiMedx net current debt from 2010 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$220.6B
Amgen (AMGN)
$158.8B
Gilead Sciences (GILD)
$136.4B
Vertex Pharmaceuticals (VRTX)
$120.4B
Bristol Myers Squibb (BMY)
$95.4B
GSK (GSK)
$78.4B
CSL (CSLLY)
$76.6B
Regeneron Pharmaceuticals (REGN)
$61.3B
Alnylam Pharmaceuticals (ALNY)
$41.1B
Argenex SE (ARGX)
$34.3B
BioNTech SE (BNTX)
$27.1B
Royalty Pharma (RPRX)
$20.2B
Biogen (BIIB)
$19.7B
Insmed (INSM)
$18.6B
Illumina (ILMN)
$15.7B
Genmab (GNMSF)
$14.2B
Genmab (GMAB)
$13.7B
Incyte (INCY)
$13.3B
Moderna (MRNA)
$13B
Exelixis (EXEL)
$12.2B
BioMarin Pharmaceutical (BMRN)
$11.1B
QIAGEN (QGEN)
$10.7B
Ascendis Pharma (ASND)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.4B
Exact Sciences (EXAS)
$9.8B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Bio-Techne Corp (TECH)
$8.5B
Blueprint Medicines (BPMC)
$8.4B
Roivant Sciences (ROIV)
$7.7B
Repligen (RGEN)
$7.3B